Literature DB >> 1492848

Dose-proportional plasma levels of the analgesic flupirtine maleate in man. Application of a new HPLC assay.

G Niebch1, H O Borbe, T Hummel, G Kobal.   

Abstract

Single oral doses of the non-opioid, centrally-acting analgesic flupirtine maleate (Katadolon, CAS 75507-68-5) were administered to healthy volunteers and the 2 h plasma levels determined with a new specific HPLC assay. 50, 100, 200, and 300 mg were ingested as the commercial capsules in a double-blind randomized cross-over design with time intervals of at least 6 d. Dose-proportionality was observed for the median 2 h plasma levels which is in agreement with dose-proportionality previously described for multiple-dose studies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1492848

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.

Authors:  Werner Siegmund; Christiane Modess; Eberhard Scheuch; Karen Methling; Markus Keiser; Ali Nassif; Dieter Rosskopf; Patrick J Bednarski; Jürgen Borlak; Bernd Terhaag
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 2.  Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states.

Authors:  H A Friedel; A Fitton
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

3.  Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.

Authors:  Muriel B Sättler; Sarah K Williams; Clemens Neusch; Markus Otto; Jens R Pehlke; Mathias Bähr; Ricarda Diem
Journal:  Am J Pathol       Date:  2008-10-02       Impact factor: 4.307

4.  Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.

Authors:  Nora Anderson; Juergen Borlak
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

5.  Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.

Authors:  Johannes Fleckenstein; Ruth Sittl; Beate Averbeck; Philip M Lang; Dominik Irnich; Richard W Carr
Journal:  J Transl Med       Date:  2013-02-08       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.